TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS
Two separate studies at ACC.25 explored data from the EARLY TAVR trial. One analysis included stroke findings that surprised researchers.
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
The positive data were presented as part of a late-breaking clinical at ACC.25 in Chicago. One cardiologist on stage for the presentation said these findings will impact the way he manages certain TAVR patients.
Cardiologists make case against routine interventions for asymptomatic severe AS
Aortic valve replacement is likely inevitable for patients with asymptomatic severe aortic stenosis. Immediately performing TAVR or SAVR, however, may not always be the answer.
So far, so good: TAVR comparable to open heart surgery after 5 years in low-risk patients
Michael J. Reardon, MD, shared the highly anticipated data with a large audience at ACC.25 in Chicago. Overall, he said, these five-year findings suggest TAVR with a supra-annular, self-expanding valve is a safe and effective alternative to SAVR.
AHA still working to find more patients with severe aortic stenosis who may require care
The initiative is designed to help identify more patients who may require aortic valve replacement. Brian Lindman, MD, provided an update on the project's efforts.

PCI before TAVR? New study provides answers, but questions remain

Researchers examined data from 17 different facilities, keeping a close eye on mortality and rehospitalization rates.

New TAVR system for high-risk patients gains FDA approval

The system was specifically designed for patients who should avoid open-heart surgery.

AI model classifies patients by aortic stenosis severity, could improve AVR timing

The classifier was developed using imaging data from nearly 2,000 patients.

3 conditions associated with a higher stroke risk among TAVR patients

The new analysis, published in Current Problems in Cardiology, also explored the higher costs associated with post-TAVR stroke.

New meta-analysis examines valve durability after 5 years among TAVR, SAVR patients

As TAVR and SAVR patients get younger, valve durability will continue to gain more and more importance.

Edoxaban comparable to VKAs for treating AFib after TAVR

Researchers shared their findings at ESC Congress 2021 and in the New England Journal of Medicine.

Paravalvular leak after TAVR continues to be a problem—but advances in technology are helping

Additional studies are still necessary, but researchers are hopeful that modern TAVR solutions will help limit paravalvular leak in the years ahead.

Number of TAVR sites has nearly tripled in recent years—but quality issues remain

While the improved access is clearly beneficial, researchers did uncover potential issues that will need to be addressed.

Around the web

Radiology Business

The impact of Trump tariffs on iodine contrast media costs

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Radiology Business

Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

TAVR

New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS

Dapagliflozin improves outcomes for elderly TAVR patients with heart failure

Cardiologists make case against routine interventions for asymptomatic severe AS

So far, so good: TAVR comparable to open heart surgery after 5 years in low-risk patients

AHA still working to find more patients with severe aortic stenosis who may require care

Around the web